Enhanced acute responses in an experimental exposure model to biomass smoke inhalation in chronic obstructive pulmonary disease

Experimental Lung Research

Volumn 34, Issue 10, 2008, Pages 631-662

  Mattson, Jeanine D ^a   Haus, Brian M ^b,c   Desai, Bela ^a   Ott, Wayne ^d   Basham, Beth ^a   Agrawal, Madhuri ^b,c   Ding, Wei ^e   Hildemann, Lynn M ^d   Abitorabi, Karin M ^a   Canfield, James ^b,c   Mak, Gordon ^b,c   Guvenc Tuncturk, Sebnem ^b,c   Malefyt, Rene De Waal ^a   McClanahan, Terrill K ^a   Fick Jr , Robert B ^a   Kuschner, Ware G ^b,c  

^a Schering Plough Biopharma ^*  (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e Discovery Technology   (Finland)

Author keywords

Chronic obstructive; Flow cytometric analysis; Forced expiratory flow; Forced expiratory volume; Forced vital capacity; Pulmonary disease; Reverse transcriptase polymerase chain reaction

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CIGARETTE SMOKE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NUCLEAR FACTOR KAPPA B1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOMASS; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURFACE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPERIMENTAL STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; MALE; MONOCYTE; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; BIOLOGICAL MARKERS; BIOMASS; CARDIOVASCULAR DISEASES; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; PARTICULATE MATTER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMOKE;

EID: 57749107491     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140802322256     Document Type: Article

References (61)

1. Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, Luepker R, Mittleman M, Samet J, Smith SC Jr, Tager I: Expert Panel on Population and Prevention Science of the American Heart Association: Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation. 2004;109:2655-2671.
2. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL: Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med. 2000;343:1742-1749.
3. Dominici F, Peng RD, Bell ML, Pham L, McDermott A, Zeger SL, Samet JM: Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. JAMA. 2006;295:1127-1134.
4. Wellenius GA, Schwartz J, Mittleman MA: Particulate air pollution and hospital admissions for congestive heart failure in seven United States cities. Am J Cardiol. 2006;97:404-408.
5. Pope CA, Muhlestein JB, May HT, Renlund DG, Anderson JL, Horne BD: Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation. 2006;114:2443-2448.
6. Pope CA, Burnett RT, Thun MJ, Calle EE, Krewski D, Ito K, Thurston GD: Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. JAMA. 2002;287:1132-1141.
7. van Eeden SF, Tan WC, Suwa T, Mukae H, Terashima T, Fujii T, Qui D, Vincent R, Hogg JC: Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med. 2001;164:826-830.
8. Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF: Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol. 2002;39:935-942.
9. Tan WC, Qiu D, Liam BL, Ng TP, Lee SH, van Eeden SF, D'Yachkova Y, Hogg JC: The human bone marrow response to acute air pollution caused by forest fires. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1213-1217.
10. Ruckerl R, Ibald-Mulli A, Koenig W, Schneider A, Woelke G, Cyrys J, Heinrich J, Marder V, Frampton M, Wichmann HE, Peters A: Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. Am J Respir Crit Care Med. 2006;173:432-441.
11. Tamagawa E, van Eeden SF: Impaired lung function and risk for stroke: role of the systemic inflammation response? Chest. 2006;130:1631-1633.
12. Kim WD, Kim WS, Koh Y, Lee SD, Lim CM, Kim DS, Cho YJ: Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest. 2002;122:437-444.
13. Barnes PJ, Shapiro SD, Pauwels RA: COPD: molecular and cellular mechanisms. Eur Respir. J 2003;22:672-688.
14. Frankenberger M, Menzel M, Betz R, Kabner G, Weber N, Kohlhaufl M, Haubinger K: Ziegler-Heitbrock L. Characterization of a population of small macrophages in induced sputum of patients with COPD and healthy volunteers. Clin Exp Immunol. 2004;138:507-516.
15. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997;155:852-857.
16. Saetta M, Baraldo S, Corbino L: CD8+ve cells in the lungs of smokers with COPD. Am J Respir Crit Care Med. 1999;160:711-717.
17. Hageman GJ, Larik I, Pennings HJ, Haenen GR, Wouters EF, Bast A: Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients. Free Radic Biol Med. 2003;35:140-148.
18. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF: Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with COPD. Thorax. 1996;51:819-824.
19. Mayer C, Gruber HJ, Landl EM, Pailer S, Scharnagl H, Truschnig-Wilders M, Marz W: Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3-and C/EBP-dependent fashion. Int J Clin Pharmacol Ther. 2007;45:319-327.
20. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995;152:1107-1136.
21. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
22. Prieto A, Reyes E, Bernstein ED, Martinez B, Monserrat J, Izquierdo JL, Callol L, de Lucas P, Alvarez-Sala R, Alvarez-Sala JL, Villarrubia VG: Alvarez-Mon M. Defective natural killer and phagocytic activities in COPD are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med. 2001;163:1578-1583.
23. Lewis SA, Pavord ID, Stringer JR, Knox AJ, Weiss ST, Britton JR: The relation between peripheral blood leukocyte counts and respiratory symptoms, atopy, lung function, and airway responsiveness in adults. Chest. 2001;119:105-114.
24. Cosio MG, Majo J, Cosio MG: Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest. 2002;121:160S-165S.
25. Pons AR, Noguera A, Blanquer D, Sauleda J, Pons J, Agusti AGN: Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. Eur Respir. J 2005;25:647-652.
26. Oudijk EJ, Nijhuis EH, Zwank MD, van de Graaf EA, Mager HJ, Coffer PJ, Lammers JW, Koenderman L: Systemic inflammation in COPD visualized by gene profiling in peripheral blood neutrophils. Thorax 2005;60:538-544.
27. Tzouvelekis A, Patlakas G, Bouros D: Application of microarray technology in pulmonary diseases. Respir Res 2004;5:26-43.
28. Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, Masuda M, Itoh H: Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir. J 2005;25:885-890.
29. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49:187-198.
30. Azimi N, Shiramizu KM, Tagaya Y, Mariner J, Waldmann TA. Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. J Virol. 2000;74:7338-7348.
31. Libermann TA, Baltimore D: Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol. 1990;10:2327-2334.
32. Kuprash DV, Osipovich OA, Pokholok DK, Alimzhanov MB, Biragyn A, Turetskaya RL, Nedospasov SA: Functional analysis of the lymphotoxin-beta promoter. Sequence requirements for PMA activation. J Immunol. 1996;156:2465-2472.
33. Yi-qun Z, Joost van Neerven RJ, Kasran A, de Boer M, Ceuppens JL: Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens. Int Immunol. 1996;8:37-44.
34. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese MC, Greenberg HB, Butcher EC: Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extra lymphoid tissue homing potential. J Clin Invest 2001;107:595-601.
35. +) T cells from secondary lymphoid organs. Blood. 2001;97:850-857.
36. + T cell differentiation in peripheral blood. Eur J Immunol. 2005;35:2608-2616.
37. Churg A, Xie C, Wang X, Vincent R, Wang RD: Air pollution particles activate NF-kappaB on contact with airway epithelial cell surfaces. Toxicol Appl Pharmacol. 2005;208:37-45.
38. Lai JH, Horvath G, Subleski J, Bruder J, Ghosh P, Tan TH: RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol Cell Biol. 1995;15:4260-4271.
39. Sancho D, Yanez-Mo M, Tejedor R, Sanchez-Madrid F: Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen-1/intercellular adhesion molecule-1 and interleukin-15. Blood. 1999;93:886-896.
40. Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 2005;52:3004-3014.
41. Agostini C, Zambello R, Facco M, Perin A, Piazza F, Siviero M, Basso U, Bortolin M, Trentin L, Semenzato G: CD8 T-cell infiltration in extra vascular tissues of patients with human immunodeficiency virus infection. Interleukin-15 upmodulates costimulatory pathways involved in the antigen-presenting cells-T-cell interaction. Blood. 1999;93:1277-1286.
42. Mattei F, Schiavoni G, Belardelli F, Tough DF: IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol. 2001;167:1179-1187.
43. Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, Roberts AI, Ebert EC, Kassam N, Qin S, Zovko M, LaRosa GJ, Yang LL, Soler D, Butcher EC, Ponath PD, Parker CM, Andrew DP: Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med. 1999;190:1241-1256.
44. van der Voort R, van Lieshout AW, Toonen LW, Sloetjes AW, van den Berg WB, Figdor CG, Radstake TR, Adema GJ: Elevated CXCL16 expression by synovialmacrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum. 2005;52:1381-1391.
45. Agostini C, Cabrelle A, Calabrese F, Bortoli M, Scquizzato E, Carraro S, Miorin M, Beghe B, Trentin L, Zambello R, Facco M, Semenzato G: Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med. 2005;172:1290-1298.
46. Morgan AJ, Guillen C, Symon FA, Huynh TT, Berry MA, Entwisle JJ, Briskin M, Pavord ID, Wardlaw AJ: Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. Clin Exp Allergy 2005;35:1572-1580.
47. + memory T cells by opposing cytokines. Science 2000;288:675-678.
48. deWaal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-924.
49. Buelens C, Willems F, Delvaux A, Pierard G, Delville JP, Velu T, Goldman M: Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995;25:2668-2672.
50. Nakagome K, Dohi M, Okunishi K, Komagata Y, Nagatani K, Tanaka R, Miyazaki J, Yamamoto K: In vivo IL-10 gene delivery suppresses airway eosinophilia and hyper-reactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation. J Immunol. 2005;174:6955-6966.
51. Aw D, Silva AB, Palmer DB: Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435-446.
52. Weng NP. Aging of the immune system: how much can the adaptive immune system adapt? Immunity. 2006;24:495-499.
53. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ: Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol. 2005;96:339-345.
54. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K: Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 2001;141:211-217.
55. Zhang D, Sun M, Samols D, Kushner I: STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem. 1996;271:9503-9509.
56. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.
57. Wettinger SB, Doggen CJ, Spek CA, Rosendaal FR, Reitsma PH: High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood 2005;105:2000-2006.
58. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, van Snick J, Kuiper J: Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 2005;112:1054-1062. Erratum in Circulation. 2005;112:e293.
59. Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V, Penninger JM, Eriksson U: T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med. 2006;203:2009-2019.
60. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957.
61. Sonderegger I, Rohn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA, Bachmann MF, Kopf M: Neutralization of IL-17 by active vaccination inhibits IL-23-dependent auto-immune myocarditis. Eur J Immunol. 2006;36:2849-2856.